牛健康市場－全球產業規模、佔有率、趨勢、機會和預測：按治療藥物、診斷藥物、地區和競爭對手分類，2021-2031年

全球牛健康市場預計將從 2025 年的 101.9 億美元大幅成長至 2031 年的 168.4 億美元，複合年成長率為 8.73%。

該市場涵蓋多種藥品、生物疫苗和專用藥用飼料添加劑，旨在診斷、預防和控制牛病。推動這一市場成長的主要動力是全球對牛肉和乳製品蛋白需求的不斷成長。而這反過來又要求進行有效的牛管理，以提高產量並降低死亡率。

此外，為符合國際貿易標準，食品安全和通用感染疾病傳播預防方面的嚴格監管要求，必須在整個農業供應鏈中實施嚴格的獸醫衛生規程。儘管市場需求強勁，但新動物療法的監管核准成本和複雜性不斷增加，是市場擴張的主要障礙。這會阻礙創新並延緩產品上市。在如此嚴峻的情況下，企業必須遵守繁瑣的合規流程。同時，畜牧業的龐大規模——例如預計到2025年美國牛的數量將達到8,670萬頭——凸顯了對這些動物產品和健康解決方案的迫切需求。

市場促進因素

推動牛健康市場發展的主要因素是全球對優質牛肉和乳製品的需求不斷成長，這促使生產商最佳化牛生產力。這種需求導致藥物治療和營養補充劑的廣泛應用，以幫助牲畜高效達到目標體重和產奶量。其經濟影響在業界顯而易見，例如，碩騰（Zoetis）的畜牧業務組合在2024年第三季實現了11%的營業收入成長。此外，龐大的國際貿易規模要求嚴格的健康管理以滿足出口標準，預計2025年全球牛肉出口量將達到約1,290萬噸。這凸顯了需要持續獸醫護理的牲畜數量龐大。

另一個重要的次要因素是傳染病和通用感染疾病的爆發日益增多，迫使所有相關人員優先考慮生物安全和預防醫學。近期爆發的疫情，例如乳牛的H5N1禽流感，促使人們迅速採用診斷方法並實施緊急衛生措施，以避免供應鏈中斷。為了應對這些威脅，大量公共資金正被投入疾病控制，以保護農業經濟，例如美國農業部在2024年5月撥款8.24億美元用於快速反應和檢測。疾病發病率的上升直接推動了對疫苗和先進生物安全技術的需求，從而增強了該行業應對不斷變化的生物風險的能力。

市場挑戰

全球牛保健市場的擴張受到新型獸藥成本不斷上漲和監管核准流程複雜等諸多因素的嚴重限制。為滿足不同司法管轄區嚴格的合規要求，生產商需要投入大量資金和時間以確保產品的安全性和有效性。而這筆巨額資金投入反過來又削弱了企業研發突破性治療方法的能力，延緩了關鍵的先進生技藥品和藥用飼料添加劑的上市，而這些對於有效的牛管理至關重要。

因此，市場產品多樣性不足，限制了應對新出現的牛疾病的選擇。冗長的合規性測試流程不僅延緩了產生收入，也阻礙了企業進入市場。動物健康研究所指出，即使到了2025年，這些嚴格的強制性審查流程仍將導致新動物用藥品的平均研發週期長達8.5年。如此漫長的周期直接阻礙了該行業快速響應緊迫的畜牧業健康需求的能力，並限制了該行業的整體成長潛力。

市場趨勢

精準動物養殖（PLF）技術的普及正在從根本上改變牛的健康市場，使畜群管理從被動觀察轉變為即時、數據驅動的主動決策。養殖戶擴大使用穿戴式感測器和智慧耳標來監測生命徵象、反芻模式和行為變化，從而在出現明顯臨床症狀之前及早發現疾病。這項技術進步使得工業規模的個人化動物照護成為可能，並顯著提高了勞動效率和治療效果。例如，默克動物保健公司的SenseHub乳牛技術，計畫在2025年8月在美國監測超過200萬乳牛。

同時，隨著人們對預防性生技藥品和免疫療法的關注度日益提高，整個產業正朝著減輕新型感染疾病威脅和減少對抗生素依賴的方向發展。相關人員優先研發創新疫苗，以保護牲畜免受影響嚴重的跨境疾病侵害，從而加速先進免疫解決方案的市場推廣。這項旨在保護食品供應鏈免受病毒爆發影響的大量公共投資，正推動著生物安全創新的積極努力。 2025年3月，美國農業部（USDA）決定撥款高達1億美元，包括研發針對牲畜高致病性禽流感的新型疫苗在內的計畫。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球牛健康市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依治療類型（疫苗、驅蟲藥、抗感染藥物、藥用飼料添加劑、其他治療方法）
  • 診斷方法（免疫診斷試驗、分子診斷、影像診斷、臨床化學、其他診斷方法）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美牛健康市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲牛健康市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區牛健康市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東與非洲牛健康市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲牛健康市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球牛健康市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Qiagen LLC
• Boehringer Ingelheim International GmbH
• Thermo Fisher Scientific Inc.
• Elanco Animal Health Inc.
• Idexx Laboratories Inc.
• Kyoritsuseiyaku Corporation
• Merck & Co Inc.
• Norbrook laboratories Ltd.
• Zeotis Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The global cattle health market is projected to expand significantly, rising from USD 10.19 billion in 2025 to USD 16.84 billion by 2031, demonstrating an 8.73% compound annual growth rate. This market includes a variety of pharmaceutical treatments, biological vaccines, and specialized medicinal feed additives designed to diagnose, prevent, and manage diseases in bovine animals. Key factors driving this growth include the increasing worldwide demand for beef and dairy proteins, which requires effective herd management to boost output and reduce fatalities.

Furthermore, stringent regulatory requirements concerning food safety and the prevention of zoonotic disease transmission are enforcing rigorous veterinary health protocols throughout agricultural supply chains to meet international trade standards. Despite this robust demand, a major obstacle to market expansion is the increasing expense and intricacy of gaining regulatory approval for new veterinary therapeutics, which can hinder innovation and delay product introductions. This demanding landscape necessitates companies navigating extensive compliance processes, even as the enormous size of the livestock sector, exemplified by the 86.7 million cattle in the U.S. in 2025, highlights the crucial and ongoing need for these veterinary products and health interventions.

Market Driver

The primary driver of the cattle health market is the escalating global demand for high-quality beef and dairy products, which drives producers to optimize herd productivity. This imperative leads to the widespread use of pharmaceutical treatments and nutritional supplements, ensuring livestock efficiently achieve desired weight and lactation targets. The financial impact is visible in the industry, as demonstrated by Zoetis's livestock portfolio achieving 11% operational revenue growth in the third quarter of 2024. Moreover, the extensive scale of international trade necessitates stringent health maintenance to meet export standards, with global beef exports projected at approximately 12.9 million tons in 2025, underscoring the vast livestock population requiring continuous veterinary attention.

A crucial secondary driver is the increasing occurrence of infectious and zoonotic bovine diseases, which compels all stakeholders to prioritize biosecurity and preventive care. Recent outbreaks, such as H5N1 in dairy herds, have spurred the rapid implementation of diagnostics and urgent health interventions to avert supply chain disruptions. In response to these threats, substantial public funding is being allocated for disease mitigation to safeguard the agricultural economy, evidenced by the USDA's allocation of $824 million in May 2024 for rapid response and testing. This elevated disease prevalence directly boosts demand for vaccines and advanced biosecurity technologies, thereby reinforcing the sector's resilience against evolving biological risks.

Market Challenge

The global cattle health market's expansion is considerably hampered by the rising costs and intricate nature of regulatory approval for new veterinary therapeutics. Adhering to these stringent compliance mandates across various jurisdictions requires manufacturers to commit significant financial resources and extensive time to ensure safety and efficacy. This substantial investment of capital consequently curtails companies' capacity to invest in the research and development of groundbreaking treatments, thereby slowing the introduction of vital advanced biologicals and medicinal feed additives necessary for effective herd management.

As a direct result, the market suffers from a lack of product diversity, which limits the available options for addressing new bovine diseases. The protracted timelines necessary for compliance testing not only delay revenue generation but also deter prospective market entrants. The Animal Health Institute noted that in 2025, the average development period for a new veterinary pharmaceutical remained at 8.5 years due to these rigorous mandatory review processes. This extended cycle directly impedes the industry's ability to swiftly address immediate livestock health requirements and constrains its overall growth potential.

Market Trends

The widespread adoption of Precision Livestock Farming (PLF) Technologies is fundamentally transforming the cattle health market, shifting herd management from reactive observation to proactive, data-driven decision-making in real-time. Farmers are increasingly utilizing wearable sensors and smart ear tags to monitor vital signs, rumination patterns, and behavioral changes, enabling early detection of illness before overt clinical symptoms manifest. This technological evolution facilitates individualized animal care at an industrial scale, significantly enhancing labor efficiency and improving treatment outcomes, as evidenced by Merck Animal Health's SenseHub Dairy Technology monitoring over 2 million dairy cows in the United States by August 2025.

Simultaneously, a growing emphasis on preventive biologics and immunotherapy is guiding the industry towards mitigating emerging infectious threats and reducing reliance on antibiotics. Stakeholders are prioritizing the creation of innovative vaccines to safeguard herds against high-impact transboundary diseases, thereby accelerating the commercial availability of advanced immunological solutions. This concentrated effort on biosecurity innovation is bolstered by substantial public investments aimed at securing the food supply chain from viral outbreaks, with the USDA allocating up to $100 million in March 2025 to fund projects including the development of novel vaccines for highly pathogenic avian influenza in livestock.

Key Market Players

• Qiagen LLC
• Boehringer Ingelheim International GmbH
• Thermo Fisher Scientific Inc.
• Elanco Animal Health Inc.
• Idexx Laboratories Inc.
• Kyoritsuseiyaku Corporation
• Merck & Co Inc.
• Norbrook laboratories Ltd.
• Zeotis Inc

Report Scope

In this report, the Global Cattle Health Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cattle Health Market, By Therapeutics

• Vaccine
• Parasiticide
• Anti-infective
• Medical Feed Additive
• Other Therapeutics

Cattle Health Market, By Diagnostics

• Immunodiagnostic Test
• Molecular Diagnostics
• Diagnostic Imaging
• Clinical Chemistry
• Other Diagnostics

Cattle Health Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cattle Health Market.

Available Customizations:

Global Cattle Health Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cattle Health Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapeutics (Vaccine, Parasiticide, Anti-infective, Medical Feed Additive, Other Therapeutics)
  • 5.2.2. By Diagnostics (Immunodiagnostic Test, Molecular Diagnostics, Diagnostic Imaging, Clinical Chemistry, Other Diagnostics)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Cattle Health Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapeutics
  • 6.2.2. By Diagnostics
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cattle Health Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapeutics
      • 6.3.1.2.2. By Diagnostics
  • 6.3.2. Canada Cattle Health Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapeutics
      • 6.3.2.2.2. By Diagnostics
  • 6.3.3. Mexico Cattle Health Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapeutics
      • 6.3.3.2.2. By Diagnostics

7. Europe Cattle Health Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapeutics
  • 7.2.2. By Diagnostics
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cattle Health Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapeutics
      • 7.3.1.2.2. By Diagnostics
  • 7.3.2. France Cattle Health Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapeutics
      • 7.3.2.2.2. By Diagnostics
  • 7.3.3. United Kingdom Cattle Health Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapeutics
      • 7.3.3.2.2. By Diagnostics
  • 7.3.4. Italy Cattle Health Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapeutics
      • 7.3.4.2.2. By Diagnostics
  • 7.3.5. Spain Cattle Health Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapeutics
      • 7.3.5.2.2. By Diagnostics

8. Asia Pacific Cattle Health Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapeutics
  • 8.2.2. By Diagnostics
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cattle Health Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapeutics
      • 8.3.1.2.2. By Diagnostics
  • 8.3.2. India Cattle Health Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapeutics
      • 8.3.2.2.2. By Diagnostics
  • 8.3.3. Japan Cattle Health Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapeutics
      • 8.3.3.2.2. By Diagnostics
  • 8.3.4. South Korea Cattle Health Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapeutics
      • 8.3.4.2.2. By Diagnostics
  • 8.3.5. Australia Cattle Health Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapeutics
      • 8.3.5.2.2. By Diagnostics

9. Middle East & Africa Cattle Health Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapeutics
  • 9.2.2. By Diagnostics
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cattle Health Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapeutics
      • 9.3.1.2.2. By Diagnostics
  • 9.3.2. UAE Cattle Health Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapeutics
      • 9.3.2.2.2. By Diagnostics
  • 9.3.3. South Africa Cattle Health Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapeutics
      • 9.3.3.2.2. By Diagnostics

10. South America Cattle Health Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapeutics
  • 10.2.2. By Diagnostics
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cattle Health Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapeutics
      • 10.3.1.2.2. By Diagnostics
  • 10.3.2. Colombia Cattle Health Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapeutics
      • 10.3.2.2.2. By Diagnostics
  • 10.3.3. Argentina Cattle Health Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapeutics
      • 10.3.3.2.2. By Diagnostics

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cattle Health Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Qiagen LLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Boehringer Ingelheim International GmbH
• 15.3. Thermo Fisher Scientific Inc.
• 15.4. Elanco Animal Health Inc.
• 15.5. Idexx Laboratories Inc.
• 15.6. Kyoritsuseiyaku Corporation
• 15.7. Merck & Co Inc.
• 15.8. Norbrook laboratories Ltd.
• 15.9. Zeotis Inc

16. Strategic Recommendations

17. About Us & Disclaimer